Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy is a treatment approach for acute myeloid leukemia (AML) that aims to overcome disease resistance and achieve better outcomes. This approach involves the use of gemtuzumab ozogamicin, a monoclonal antibody that targets CD33-positive leukemia cells, in combination with intensive chemotherapy. The goal is to induce complete remission and improve survival rates in patients with AML. By combining targeted therapy with intensive chemotherapy, this approach has shown promise in improving treatment outcomes and reducing the risk of relapse.